Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Arch Biopartners Inc V.ARCH

Alternate Symbol(s):  ACHFF

Arch Biopartners Inc. is a late-stage clinical trial company focused on preventing acute kidney injury. The Company is developing a platform of new drugs to prevent inflammation injury in the kidneys, lungs and liver via the dipeptidase-1 (DPEP1) pathway and are relevant for many common injuries and diseases where organ inflammation is an unmet problem. The Company’s lead drug candidate is LSALT Peptide. The Company is engaged in the clinical development of LSALT Peptide and other DPEP-1 targeting drug candidates for indications where inflammation of the lungs, liver and kidneys is an unmet problem. LSALT Peptide is in a second phase II trial, targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). The Company has additional technology platforms in its portfolio, which are AB569 and Borg. AB569 is an anti-infective candidate for treating or preventing antibiotic resistant bacterial infections, primarily as a topical treatment for wounds.


TSXV:ARCH - Post by User

Comment by Riverfolkon Dec 02, 2021 1:36pm
82 Views
Post# 34191072

RE:RE:RE:RE:RE:RE:Calgary herald

RE:RE:RE:RE:RE:RE:Calgary heraldThe Market is being extremely inefficient, I cant argue that at all. Just as it was when the governement funding for phase II was announced. The biosciences Sector is extremely difficult to understand and for most they get emotional in times what should be jovial.

The data from Phase II is currently waiting on the publication, which will derisk further for those who want to enter with funds etc. Statistically speaking Metablok/Lsalt Peptide increased the probability of success in regulatory approval yesturday from 15-53%. The clear signal in the Data that was released now brings credability to the entire Dipep-1 library of 8 drugs.

Fully Patented and a decade ahead of any pears in the human trial process, I have never felt better as a long term shareholder. The Facts are laid out in the news release, If you dont think the market beleives the facts becuase they are too good, that is when I typically buy more shares.

Great Discussion guys, I am very pleased with proceeding into a Phase III trial that is conducted by CATCO and Fully Funded by the Governement. It pleases me Greatly that the Company has the drug on hand to perform this trial and with Health Canada approval the timeline to potentially substantial shareholder growth is alot closer.
<< Previous
Bullboard Posts
Next >>